Search

• GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020

  Media

  GSK announced it has joined other global pharma companies and organisations in a united effort to defeat neglected tropical diseases.

  https://www.gsk.com/en-gb/media/press-releases/gsk-joins-new-global-partnership-to-help-defeat-ten-neglected-tropical-diseases-by-2020/

  First published: 30 January 2012

• GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19

  Media

  Review will support a formal Marketing Authorisation Application.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19/

  First published: 07 May 2021

• Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

  Media

  Initial Phase 3 results may be available as early as the end of 2020; complete results are anticipated in January 2021.

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/

  First published: 06 October 2020

• Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19

  Media

  GSK and Vir are committed to the ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve

  https://www.gsk.com/en-gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-european-commission-for-the-early-treatment-of-covid-19/

  First published: 17 December 2021

• Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

  Media

  Phase III IM administration data for sotrovimab.

  https://www.gsk.com/en-gb/media/press-releases/primary-endpoint-met-in-comet-tail-phase-iii-trial-evaluating-intramuscular-administration-of-sotrovimab-for-early-treatment-of-covid-19/

  First published: 12 November 2021

• Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant

  Media

  Data to be confirmed by further in vitro pseudo-virus testing

  https://www.gsk.com/en-gb/media/press-releases/preclinical-data-demonstrate-sotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/

  First published: 02 December 2021

• Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant

  Media

  New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv

  https://www.gsk.com/en-gb/media/press-releases/sotrovimab-retains-activity/

  First published: 07 December 2021

• GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

  Media

  600,000 additional doses to be supplied to the US Government for distribution in Q1 2022

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/

  First published: 11 January 2022

• GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics

  Media

  GSK & BARDA have agreed to support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-awarded-up-to-200-million-by-us-government-to-develop-new-antibiotics/

  First published: 22 May 2013

• Results announcement for the fourth quarter 2016

  Media

  View full Q4 2016 Results (PDF)

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/

  First published: 08 February 2017